<?xml version="1.0" encoding="UTF-8"?>
<p>Other treatments in the pipeline could be further investigated against COVID-19 such as neutralizing antibodies, passive antibodies (patient sera) and ACE2 receptor-blocking agents [
 <xref rid="B22" ref-type="bibr">22</xref>,
 <xref rid="B23" ref-type="bibr">23</xref>,
 <xref rid="B33" ref-type="bibr">33</xref>,
 <xref rid="B108" ref-type="bibr">108</xref>,
 <xref rid="B109" ref-type="bibr">109</xref>]. Importantly, umbilical cord mesenchymal stem cells have been tried as a therapeutic option against COVID-19 to prevent the cytokine storm, which is thought to be induced by an overactivated immune system in response to the virus [
 <xref rid="B110" ref-type="bibr">110</xref>]. Moreover, recent studies have shown that the use of famotidine, a histamine-2 receptor antagonist, is associated with a reduction in clinical deterioration of patients with COVID-19 [
 <xref rid="B111" ref-type="bibr">111</xref>,
 <xref rid="B112" ref-type="bibr">112</xref>].
</p>
